UK Community Advisory Board

09/10/2023

https://i-base.info/htb/date/2023/10
October HTB online. LGBTQI+ violence in Uganda, pregnancy, ADVANCE and more in this double issue...

30/12/2022

Remembering Giulio Maria Corbelli and Chris Sandford, latest UK statistics, reports from Glasgow and IAS meetings, CHAI on global access to ART, BHIVA guidelines and more...
https://i-base.info/htb/date/2022/12

29/12/2022

Remembering Giulio Maria Corbelli and Chris Sandford, latest UK statistics, reports from Glasgow and IAS meetings, CHAI on global access to ART, BHIVA guidelines and more...

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

05/12/2022

The UK-CAB online training programme is an introduction to HIV treatment, research and treatment advocacy for people living with HIV, affected by HIV, or working in the HIV sector. Presented by people from the HIV community, leading clinicians and experts, it is free for all UK-CAB members.

The course will go out fortnightly live, followed by a live Q&A with panellists and speakers. Recordings will then be available online for people who miss the live session and for anyone who would like to watch again.

To join UK-CAB, click on this link: https://ukcab.net/about/join/

The UK-CAB network is free to join and open to anyone living with HIV in the UK, affected by HIV or working in the HIV sector, other than pharmaceutical companies and their agencies.

What the training is about:

The online training programme is in three sections, with each section including 5 or 6 one-hour modules:

Section 1: HIV treatment *BOOKING NOW*
Starts Monday 10th January 2023 at 7pm, every two weeks thereafter.
Section 2: Evidence-based medicine and clinical trials *COMING SOON*
Section 3: Living with HIV, HIV treatment and advocacy *COMING SOON*

Module 1.1 – HIV History
This section begins with an outline of how the AIDS epidemic began, the impact on the general population and the rise of AIDS activism from Ben Cromarty. This is followed by a panel discussion from Dr Duncan Churchill, Consultant. University Hospitals Sussex NHS Foundation Trust; the late Chris Sandford, HIV activist and historian, peer support worker and Education Director, National HIV Story Trust and Haemophilia and HIV activist, Lecturer, Sussex University.

Click here to register for Tuesday 10 January 7.00 pm: https://tinyurl.com/bdhpewsc

You will only need to register once for the entire training. The link to the meeting will be shared with the registered participants closer to the date.

Please do not hesitate to contact me for any queries or clarifications.

Please share widely amongst your networks.

Note: CAB membership is not open to people who work for drug company involved in HIV research. This also applies to employees of PR, marketing and other professional companies whose clients include HIV drug companies. The CAB works closely with industry, and appreciates this collaboration. But the U...

25/07/2022

MPX vaccine is very safe and effective, but might take 2-4 weeks to work, better after two shots, HIV might reduce responses, childhood vaccine might help.
https://i-base.info/qa/20255

03/07/2022

July HTB: monkeypox crisis in UK and PRIDE - plus CROI, COVID, bNAbs, ANCHOR, PrEP and UNAIDS - acronyms in the news... :)
https://i-base.info/htb/43339

22/06/2022

From HIV i-Base:
UK plans to offer vaccine to gay and bisexual men at risk of monkeypox.

UK plans to offer vaccine to gay and bisexual men at risk of monkeypox 21 June 2022. Related: Early access. Simon Collins, HIV i-Base On 21 June 2022, the UKHSA announced plans to offer a vaccine against monkeypox (MPX) to (some) gay and bisexual men. [1] Although this strategy has been wanted by ma...

06/06/2022

This Q&A is about the recent cases of monkeypox (MPX) in the UK. At some point this name may be changed.

This page will be updated as new information becomes available. Last update 5 June 2022.

Monkeypox (MPX) is still very rare in the UK. But the recent outbreak is significant and needs to be taken seriously. For example, the WHO define one case in a country as an outbreak.

Monkeypox: Q&A and resources 5 June 2022. Related: News. Simon Collins, HIV i-Base and Alex Sparrowhawk, UK-CAB MPV blister on a hand (US CDC) This Q&A is about the recent cases of monkeypox (MPX) in the UK. At some point this name may be changed. This page will be updated as new information becomes...

09/05/2022

HTB May 2022: Support Ukraine; NADIR, VISEND and COVID studies; ibalizumab access in EU; justice for Zak Kostopoulos still needed...
https://i-base.info/htb/date/2022/05

18/11/2021

NICE approves injectable HIV treatment. Access expected by April 2022 for up to 15% of people living with HIV. https://i-base.info/htb/41623

18/11/2021

NICE decision on cabotegravir with rilpivirine (Long-Acting Injectables): Community Statement from UK-CAB (UK Community Advisory Board) and National AIDS Trust

See article here: https://tinyurl.com/ykwrtama

NICE approves first long-acting injectable treatment for people living with HIV

The National Institute for Health and Care Excellence (NICE) has approved cabotegravir with rilpivirine (CAB/RPV) as an option for treating adults with HIV in England and Wales. Provided the decision is not appealed, this means next year, people living with HIV in England and Wales will be able to access the first long-acting injectable used to treat HIV, an alternative option to taking daily pills.

People living with HIV must meet the following criteria before they can be considered for a switch to the CAB/RPV long-acting injectable:

An undetectable viral load (less than 50 copies/ml) whilst on an existing HIV treatment. No history of resistance or virological failure to any non-nucleoside reverse transcriptase inhibitors (NNRTIs) or integrase inhibitors (INIs), due to the risk the drugs will not work effectively.

What happens now?

The new treatment is not available immediately. There are a number of steps before the new treatment will be available from HIV clinics:

Thursday 18 November 2021: Final Appraisal Document (draft guidance) published Thursday 2 December 2021: Stakeholders appeals period closes. Grounds for appeal are strict, and are only considered if stakeholders believe NICE failed to act fairly or exceeded their powers, or the recommendation is unreasonable in the light of evidence submitted to NICE.

Wednesday 5 January 2022: The expected publication date of the recommendations (assuming no appeals are upheld). Legally new treatments must be available in Wales two months from this date, and three months in England.

Early March 2022: NHS Wales must start providing the treatment, unless an implementation extension is requested and granted.
Early April 2022: NHS England must start providing the treatment, we do not expect an implementation extension.
What about people living with HIV in Scotland and Northern Ireland?

Last month the Scottish Medicines Consortium (SMC) approved the use of the treatment for people living with HIV in Scotland. Decisions on treatment availability in Scotland are made at Health Board level. Waverley Care, THT Scotland and National AIDS Trust are writing to all the Boards to encourage consistent implementation and ensure that the treatment is available to anyone in Scotland who would benefit from it.

It is our understanding that it is usual process for Northern Ireland to follow recommendations made in England and Wales.

Acknowledgements

NAT and UK-CAB would like to thank colleagues at Africa Advocacy Foundation, HIV i-Base, NAM aidsmap, Positively UK and Terrence Higgins Trust for their support and contributions throughout the technology appraisal process.

NICE decision on cabotegravir with rilpivirine (Long-Acting Injectables) Community Statement from UK-CAB (UK Community Advisory Board) and National AIDS Trust The National Institute for Health and Care Excellence (NICE) has+ Read More